Candel Therapeutics, Inc.
NasdaqGM:CADL Stock Report
Candel Therapeutics Past Earnings Performance Candel Therapeutics's earnings have been declining at an average annual rate of -17%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 62.3% per year.
Key information
-17.0%
Earnings growth rate
Biotechs Industry Growth 17.0% Revenue growth rate -62.3% Return on equity n/a Net Margin n/a Last Earnings Update 30 Jun 2024
Recent past performance updates
Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.30 loss in 3Q 2022) Nov 10
First half 2023 earnings released: US$0.64 loss per share (vs US$0.17 loss in 1H 2022) Aug 14
First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.03 loss in 1Q 2022) May 12
Full year 2022 earnings released: US$0.65 loss per share (vs US$1.91 loss in FY 2021) Mar 31
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 16
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 11
Show all updates
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway Jul 01
Candel Therapeutics, Inc., Annual General Meeting, Jun 26, 2024 May 31
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting May 25
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer Apr 15
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors Apr 12
Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Apr 05
New major risk - Share price stability Apr 05
Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma Mar 29
Candel Therapeutics, Inc. Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate Mar 06
Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma Feb 15 Candel Therapeutics, Inc. Announces Chief Financial Officer Changes
Candel Therapeutics, Inc. Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer Dec 13
Candel Therapeutics Receives Non-Compliance Notice from Nasdaq Nov 24
Candel Therapeutics Receives Non-Compliance Notice from Nasdaq Nov 22
Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.30 loss in 3Q 2022) Nov 10
New major risk - Share price stability Nov 07
Candel Therapeutics, Inc. Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Nov 04
Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110 Oct 20
Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110 Oct 19
Candel Therapeutics, Inc. Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer Sep 27
Price target increased by 8.6% to US$9.50 Sep 19
First half 2023 earnings released: US$0.64 loss per share (vs US$0.17 loss in 1H 2022) Aug 14
New major risk - Financial position Jul 01
New major risk - Share price stability Jun 25
Candel Therapeutics, Inc. Appoints Nicoletta Loggia to the Board of Directors Jun 09
Candel Therapeutics, Inc., Annual General Meeting, Jun 28, 2023 May 25
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of Can-3110 in Recurrent High-Grade Glioma At the American Society of Gene & Cell Therapy 26Th Annual Meeting May 20
Price target decreased by 17% to US$7.25 May 16
First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.03 loss in 1Q 2022) May 12
Full year 2022 earnings released: US$0.65 loss per share (vs US$1.91 loss in FY 2021) Mar 31
Independent Director recently bought US$73k worth of stock Dec 13
Consensus forecasts updated Dec 10
Price target decreased to US$11.60 Dec 09
Candel Therapeutics, Inc. R&D Day Presentations Spotlight Its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer Dec 09
Candel Therapeutics Announces Oral Presentation of Updated Data from Its Phase 1 Clinical Trial of Can-3110 in 41 Patients with Recurrent High-Grade Glioma At the Society for Neuro-Oncology 27Th Annual Meeting Nov 19
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 16
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma Nov 12
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 11
Candel gets European orphan drug designation for brain, spinal cord tumor treatment Sep 15 Candel Therapeutics Announces Jason A. Amello as Chief Financial Officer, Effective September 21, 2022
Candel Therapeutics appoints CFO, chief medical officer Sep 07
Candel Therapeutics, Inc., Annual General Meeting, Oct 13, 2022 Sep 03
Consensus forecasts updated Aug 31
Consensus forecasts updated Aug 17
Less than half of directors are independent Aug 10
First half 2022 earnings released Aug 05
Candel Therapeutics, Inc. Announces Executive Changes Aug 02
Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell Microcap Value Index Jun 26
Candel Therapeutics, Inc. Releases Initial Data on CAN-2409 in A Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer May 27
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 13
Consensus forecasts updated Apr 05
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 30
Candel Therapeutics, Inc Expects to Present Initial Data from an Ongoing Phase 2 Clinical Trial of CAN-2409 Mar 30
Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer Mar 04
Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer Mar 03
Candel Therapeutics, Inc. Appoints Dr. Francesca Barone as Chief Scientific Officer Feb 04
Candel Therapeutics, Inc. Removes Estuardo Aguilar-Cordova and Laura Aguilar from the Board Feb 01
Candel Therapeutics, Inc. and Partnership for Accelerating Cancer Therapies to Collaborate on Lung Cancer Trial for CAN-2409 Dec 11
Third quarter 2021 earnings released: US$0.69 loss per share Nov 15
Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies Oct 21
Chairman recently bought US$411k worth of stock Jul 31
Revenue & Expenses Breakdown
How Candel Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History NasdaqGM:CADL Revenue, expenses and earnings (USD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Jun 24 0 -50 14 0 31 Mar 24 0 -37 14 0 31 Dec 23 0 -38 14 0 30 Sep 23 0 -32 14 0 30 Jun 23 0 -32 15 0 31 Mar 23 0 -27 15 0 31 Dec 22 0 -19 15 0 30 Sep 22 0 -12 16 0 30 Jun 22 0 -20 15 0 31 Mar 22 0 -33 13 0 31 Dec 21 0 -36 11 0 30 Sep 21 0 -48 10 3 30 Jun 21 0 -35 8 8 31 Mar 21 0 -20 7 8 31 Dec 20 0 -18 6 8 31 Dec 19 0 -8 3 0
Quality Earnings: CADL is currently unprofitable.
Growing Profit Margin: CADL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CADL is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare CADL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CADL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CADL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity .
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}